COHEN & STEERS INC (CNS) Stock Fundamental Analysis
USA - NYSE:CNS - US19247A1007 - Common Stock
70.71 USD
+1.87 (+2.72%)
70.71 USD
0 (0%)
Overall CNS gets a fundamental rating of 5 out of 10. We evaluated CNS against 236 industry peers in the Capital Markets industry. While CNS belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. CNS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CNS had positive earnings in the past year.
In the past year CNS has reported a negative cash flow from operations.
Each year in the past 5 years CNS has been profitable.
Each year in the past 5 years CNS had a positive operating cash flow.
1.2 Ratios
CNS has a better Return On Assets (21.59%) than 98.73% of its industry peers.
With an excellent Return On Equity value of 30.67%, CNS belongs to the best of the industry, outperforming 95.34% of the companies in the same industry.
CNS has a Return On Invested Capital of 25.18%. This is amongst the best in the industry. CNS outperforms 98.31% of its industry peers.
CNS had an Average Return On Invested Capital over the past 3 years of 28.30%. This is significantly above the industry average of 7.56%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.59% | ||
| ROE | 30.67% | ||
| ROIC | 25.18% |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
1.3 Margins
Looking at the Profit Margin, with a value of 29.82%, CNS is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
CNS's Profit Margin has declined in the last couple of years.
CNS has a Operating Margin of 33.62%. This is in the better half of the industry: CNS outperforms 61.86% of its industry peers.
CNS's Operating Margin has declined in the last couple of years.
CNS has a better Gross Margin (88.71%) than 92.80% of its industry peers.
In the last couple of years the Gross Margin of CNS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.62% | ||
| PM (TTM) | 29.82% | ||
| GM | 88.71% |
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
2. Health
2.1 Basic Checks
CNS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CNS has been increased compared to 5 years ago.
CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
CNS has an Altman-Z score of 10.73. This indicates that CNS is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 10.73, CNS belongs to the best of the industry, outperforming 94.92% of the companies in the same industry.
CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 10.73 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
CNS has a Current Ratio of 0.87. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
CNS's Current ratio of 0.87 is on the low side compared to the rest of the industry. CNS is outperformed by 63.56% of its industry peers.
A Quick Ratio of 0.87 indicates that CNS may have some problems paying its short term obligations.
The Quick ratio of CNS (0.87) is worse than 63.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.87 | ||
| Quick Ratio | 0.87 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 8.87% over the past year.
Measured over the past 5 years, CNS shows a small growth in Earnings Per Share. The EPS has been growing by 2.50% on average per year.
CNS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.26%.
CNS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.72% yearly.
EPS 1Y (TTM)8.87%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%5.19%
Revenue 1Y (TTM)11.26%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%6.39%
3.2 Future
CNS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.06% yearly.
Based on estimates for the next years, CNS will show a quite strong growth in Revenue. The Revenue will grow by 8.09% on average per year.
EPS Next Y4.56%
EPS Next 2Y8.74%
EPS Next 3Y8.1%
EPS Next 5Y13.06%
Revenue Next Year7.44%
Revenue Next 2Y8.98%
Revenue Next 3Y7.58%
Revenue Next 5Y8.09%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 23.03, the valuation of CNS can be described as rather expensive.
61.02% of the companies in the same industry are cheaper than CNS, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of CNS to the average of the S&P500 Index (27.67), we can say CNS is valued inline with the index average.
Based on the Price/Forward Earnings ratio of 20.41, the valuation of CNS can be described as rather expensive.
CNS's Price/Forward Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.33, CNS is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.03 | ||
| Fwd PE | 20.41 |
4.2 Price Multiples
75.42% of the companies in the same industry are more expensive than CNS, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 17.61 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CNS does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of CNS may justify a higher PE ratio.
PEG (NY)5.05
PEG (5Y)9.22
EPS Next 2Y8.74%
EPS Next 3Y8.1%
5. Dividend
5.1 Amount
CNS has a Yearly Dividend Yield of 3.51%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 8.56, CNS has a dividend in line with its industry peers.
CNS's Dividend Yield is a higher than the S&P500 average which is at 2.35.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.51% |
5.2 History
The dividend of CNS decreases each year by -7.12%.
CNS has been paying a dividend for at least 10 years, so it has a reliable track record.
CNS has decreased its dividend in the last 3 years.
Dividend Growth(5Y)-7.12%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
CNS pays out 76.12% of its income as dividend. This is not a sustainable payout ratio.
DP76.12%
EPS Next 2Y8.74%
EPS Next 3Y8.1%
70.71
+1.87 (+2.72%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners60.28%
Inst Owner Change-0.51%
Ins Owners22.51%
Ins Owner Change-0.31%
Market Cap3.61B
Revenue(TTM)552.79M
Net Income(TTM)162.12M
Analysts48
Price Target79.56 (12.52%)
Short Float %7.24%
Short Ratio7.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.51% |
Yearly Dividend2.39
Dividend Growth(5Y)-7.12%
DP76.12%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-3.28%
Min EPS beat(2)-4.27%
Max EPS beat(2)-2.29%
EPS beat(4)0
Avg EPS beat(4)-2.29%
Min EPS beat(4)-4.27%
Max EPS beat(4)-0.35%
EPS beat(8)2
Avg EPS beat(8)-1.05%
EPS beat(12)5
Avg EPS beat(12)0.61%
EPS beat(16)9
Avg EPS beat(16)2.23%
Revenue beat(2)1
Avg Revenue beat(2)0.36%
Min Revenue beat(2)-1.18%
Max Revenue beat(2)1.91%
Revenue beat(4)2
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-11.33%
Max Revenue beat(4)6.21%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.09%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.65%
EPS NY rev (1m)0.16%
EPS NY rev (3m)0.33%
Revenue NQ rev (1m)-0.28%
Revenue NQ rev (3m)-0.46%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)1.15%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.03 | ||
| Fwd PE | 20.41 | ||
| P/S | 6.63 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 6.82 | ||
| P/tB | 7.09 | ||
| EV/EBITDA | 17.61 |
EPS(TTM)3.07
EY4.34%
EPS(NY)3.46
Fwd EY4.9%
FCF(TTM)-2.4
FCFYN/A
OCF(TTM)-2.28
OCFYN/A
SpS10.66
BVpS10.36
TBVpS9.97
PEG (NY)5.05
PEG (5Y)9.22
Graham Number26.75
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.59% | ||
| ROE | 30.67% | ||
| ROCE | 32.81% | ||
| ROIC | 25.18% | ||
| ROICexc | 30.38% | ||
| ROICexgc | 34.72% | ||
| OM | 33.62% | ||
| PM (TTM) | 29.82% | ||
| GM | 88.71% | ||
| FCFM | N/A |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
ROICexc(3y)52.58%
ROICexc(5y)66.96%
ROICexgc(3y)63.61%
ROICexgc(5y)82.87%
ROCE(3y)36.88%
ROCE(5y)49.77%
ROICexgc growth 3Y-36.94%
ROICexgc growth 5Y-14.2%
ROICexc growth 3Y-34.4%
ROICexc growth 5Y-13.57%
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
F-Score5
Asset Turnover0.72
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 55.86% | ||
| Cap/Sales | 1.16% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.87 | ||
| Quick Ratio | 0.87 | ||
| Altman-Z | 10.73 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)429.54%
Cap/Depr(5y)277.84%
Cap/Sales(3y)4.88%
Cap/Sales(5y)3.14%
Profit Quality(3y)59.63%
Profit Quality(5y)81.14%
High Growth Momentum
Growth
EPS 1Y (TTM)8.87%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%5.19%
EPS Next Y4.56%
EPS Next 2Y8.74%
EPS Next 3Y8.1%
EPS Next 5Y13.06%
Revenue 1Y (TTM)11.26%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%6.39%
Revenue Next Year7.44%
Revenue Next 2Y8.98%
Revenue Next 3Y7.58%
Revenue Next 5Y8.09%
EBIT growth 1Y16.09%
EBIT growth 3Y-12.76%
EBIT growth 5Y1.55%
EBIT Next Year17.56%
EBIT Next 3Y18.41%
EBIT Next 5Y14.36%
FCF growth 1Y-196.88%
FCF growth 3Y-29.26%
FCF growth 5Y-9.31%
OCF growth 1Y-177.85%
OCF growth 3Y-26.44%
OCF growth 5Y-7.32%